Stock Ratings of Solventum and GE HealthCare: Essential Lessons on Successful Spinoffs
Stock Ratings of Solventum a...
Subscribe to Newsletter

Stock Ratings of Solventum and GE HealthCare: Essential Lessons on Successful Spinoffs

30 May 2024
2 min.
Stock Ratings of Solventum and GE HealthCare: Essential Lessons on Successful Spinoffs

Wall Street’s Verdict

Wall Street's latest ratings on Solventum and GE HealthCare Technologies offer valuable insights into evaluating spinoff companies.

Analyst Ratings

Goldman Sachs analyst David Roman initiated coverage on Solventum, recently spun off from 3M, rating it as "Sell" with a $54 price target. GE HealthCare Technologies, formerly part of GE, received a "Hold" rating with an $87 price target.

Market Performance

Early trading saw Solventum shares fall 2.4% to $58.28 and GE HealthCare shares drop 1.2% to $77.48. Meanwhile, the S&P 500 and Nasdaq were down 0.3% and 0.2%, respectively.

Challenges and Growth

Solventum faces stagnant sales growth, with analysts expecting flat sales through 2025. Management plans to invest in sales, R&D, and acquisitions but must also manage significant debt, with a leverage ratio of 3.8 times EBITDA.

GE HealthCare, with more time since its spinoff, has reduced its debt-to-EBITDA ratio to below 2 times. Its 2024 sales growth is expected at 3%, lower than the 6% projected for Siemens Healthineers. Roman's "Hold" rating reflects this balanced outlook.

Investor Concerns

Investor caution persists due to parent companies retaining stakes — GE holds 31 million GE HealthCare shares, and 3M retains 20% of Solventum, indicating potential stock sales.

Success Story

GE Vernova, another GE spinoff, started debt-free and without retained stakes, leading to a 50% stock surge since its launch. Investors are optimistic about Vernova’s earnings growth, valuing it highly.

Investment Outlook

Investors should consider management's capabilities, business outlook, and challenges like debt and potential stock sales. With GE HealthCare nearing independence from GE's shareholding, it may become more attractive for growth-focused investors.

Current Ratings

Solventum has no "Buy" ratings among its four analyst reviews, with a $66 price target. GE HealthCare has 17 ratings with a 65% Buy ratio and a $93 price target. GE Vernova enjoys a 58% Buy ratio across 12 ratings and a $171 price target, recently closing at $177.32.

In conclusion, while Solventum faces significant hurdles, GE HealthCare and GE Vernova present more balanced or optimistic outlooks, with Vernova exemplifying a successful spinoff strategy.

Companies5 in the news

Source foto:
Rating companies
15 Mention
14 Mention
12 Mention
10 Mention
Ford Motor Company
10 Mention
JP Morgan Chase
9 Mention
White House
7 Mention


News from is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York. news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director
Died this year
Born this year